People · Operator
Named in public records as an officer, director or promoter · active 2018–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tasca Therapeutics Corp | — | Biotechnology | Series C | $48.1M | $372.7M | 2024 |
| Quentis Therapeutics, Inc. | — | Biotechnology | Series B | $22.7M | $780.9M | 2018 |
Michael Aberman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Aberman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Amy Schulman | 1 | 11 |
| Carlo Rizzuto | 1 | 7 |
| Michael Foley | 1 | 3 |
| David Fallace | 1 | 2 |
| Praveen Tipirneni | 1 | 2 |
| Seth Lieblich | 1 | 1 |
| Drew King | 1 | 1 |
| Milenko Cicmil | 1 | 1 |
| Xu Wu | 1 | 1 |
| Michael Finn Foley, Ph.D. | 1 | 1 |
| Joseph P. Vacca, Ph.D | 1 | 1 |
| B. Finn Peter | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.